Work

Treatment of multiple myeloma with selinexor: a review

Year: 2024

Type: review

Abstract: Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary to explore new drugs for the treatment of MM. This review summarizes the mechanism of action of selinexor, relevant primary clinical trials, and recent developments in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma. Selinexor may be useful for the treatment of refractory MM.

Source: Therapeutic Advances in Hematology

DOI: 10.1177/20406207231219442

Authors: Qianlei Huang, Ranran Zhao, Lu Xu, Xinbao Hao, Shi Tao

Institutions: Hainan Medical University, Second Affiliated Hospital of Xuzhou Medical College

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,650